Related Experiment Video
Updated: May 13, 2026
05:23
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective
Sharef Waadallah Sharef1, Maya Al-Hajri, Ismail Beshlawi
1Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman.
European Journal of Haematology
|March 16, 2013
Summary
A lower initial dose of hydroxyurea (HU) in sickle cell disease (SCD) patients is safe and effective. This approach achieved similar clinical benefits to higher doses, reducing vaso-occlusive crises and acute chest syndrome.
Area of Science:
- Hematology
- Pediatric Medicine
- Pharmacology
Background:
- Hydroxyurea (HU) is the standard treatment for severe sickle cell disease (SCD) in children.
- Standard HU dosing ranges from 15-20 mg/kg/day, escalating to 35 mg/kg/day.
- Ethnic neutropenia necessitates careful use of myelosuppressive drugs in certain populations.
Purpose of the Study:
- To evaluate the efficacy and safety of a lower initial dose of HU with cautious dose escalation in pediatric SCD patients.
- To determine if a reduced starting dose impacts treatment outcomes compared to standard protocols.
Main Methods:
- Retrospective and prospective analysis of 161 SCD patients treated with HU at Sultan Qaboos University Hospital (1998-2011).
- Patients received an initial HU dose of 10-12 mg/kg/day, adjusted based on response and side effects.
- Patients were categorized into low-dose (10-15.9 mg/kg/day) and high-dose (16-26 mg/kg/day) groups.
Main Results:
- Significant reductions in annual vaso-occlusive crisis admissions were observed in both low- and high-dose HU groups (P < 0.001).
- No statistically significant difference in efficacy was found between the low- and high-dose groups (P > 0.05).
- Both groups showed comparable improvements in laboratory markers (Hb, MCV, ANC) and clinical outcomes like acute chest syndrome; all patients tolerated treatment well with reversible toxicities.
Conclusions:
- A lower initial dose regimen of HU is a safe and feasible option for managing sickle cell disease in children.
- This approach maintains treatment efficacy without compromising safety, offering a viable alternative for managing SCD.
- Cautious dose escalation ensures optimal therapeutic benefits while mitigating risks associated with myelosuppressive agents.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...